These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31156634)

  • 1. HLA-Class II Artificial Antigen Presenting Cells in CD4
    Couture A; Garnier A; Docagne F; Boyer O; Vivien D; Le-Mauff B; Latouche JB; Toutirais O
    Front Immunol; 2019; 10():1081. PubMed ID: 31156634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
    Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
    Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-based modulation of CD4
    Isser A; Silver AB; Pruitt HC; Mass M; Elias EH; Aihara G; Kang SS; Bachmann N; Chen YY; Leonard EK; Bieler JG; Chaisawangwong W; Choy J; Shannon SR; Gerecht S; Weber JS; Spangler JB; Schneck JP
    Nat Commun; 2022 Oct; 13(1):6086. PubMed ID: 36241639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
    La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
    Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
    Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
    Front Immunol; 2018; 9():776. PubMed ID: 29867922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.
    Butler MO; Ansén S; Tanaka M; Imataki O; Berezovskaya A; Mooney MM; Metzler G; Milstein MI; Nadler LM; Hirano N
    Int Immunol; 2010 Nov; 22(11):863-73. PubMed ID: 21059769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
    Hess AD; Thoburn CJ
    Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
    Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.
    Maus MV; Riley JL; Kwok WW; Nepom GT; June CH
    Clin Immunol; 2003 Jan; 106(1):16-22. PubMed ID: 12584046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
    Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
    J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
    Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
    Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies.
    Hasan AN; Selvakumar A; Doubrovina E; Riviere I; Sadelain MW; O'Reilly RJ
    Discov Med; 2009 Dec; 8(43):210-8. PubMed ID: 20040272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
    Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
    Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technological advances in adoptive immunotherapy.
    Oelke M; Krueger C; Schneck JP
    Drugs Today (Barc); 2005 Jan; 41(1):13-21. PubMed ID: 15753966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses.
    Caserta S; Alessi P; Guarnerio J; Basso V; Mondino A
    Cancer Res; 2008 Apr; 68(8):3010-8. PubMed ID: 18413771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
    Oelke M; Schneck JP
    Immunol Res; 2010 Jul; 47(1-3):248-56. PubMed ID: 20087680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tolerogenic Artificial APC Durably Ameliorates Experimental Autoimmune Encephalomyelitis by Directly and Selectively Modulating Myelin Peptide-Autoreactive CD4
    Wan X; Pei W; Shahzad KA; Zhang L; Song S; Jin X; Wang L; Zhao C; Shen C
    J Immunol; 2018 Aug; 201(4):1194-1210. PubMed ID: 29987163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.
    Lu XL; Liang ZH; Zhang CE; Lu SJ; Weng XF; Wu XW
    Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):157-63. PubMed ID: 16518539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.